Research programme: antitoxin monoclonal antibodies - Mapp Biopharmaceutical

Drug Profile

Research programme: antitoxin monoclonal antibodies - Mapp Biopharmaceutical

Latest Information Update: 13 Mar 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mapp Biopharmaceutical
  • Developer Iowa State University; Mapp Biopharmaceutical; Tulane National Primate Research Center; University of California, Davis; Wadsworth Center of New York State Department of Health
  • Class Antitoxins; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections; Ricin poisoning; Staphylococcal infections

Most Recent Events

  • 24 Jan 2015 Preclinical trials in Clostridium infections in USA (Parenteral)
  • 24 Jan 2015 Preclinical trials in Ricin poisoning in USA (Parenteral)
  • 24 Jan 2015 Preclinical trials in Staphylococcal infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top